Dr Reddys Laboratories (RDY) Net Income towards Common Stockholders (2009 - 2023)

Dr Reddys Laboratories (RDY) has reported Net Income towards Common Stockholders for 15 consecutive years, with $178.0 million the latest figure, recorded in Q2 2023.

• Quarterly Net Income towards Common Stockholders changed N/A year-over-year to $178.0 million in Q2 2023, while the trailing twelve-month figure through Mar 2026 was $178.0 million (down 48.7% YoY) and the FY2026 annual result came in at $456.0 million, down 31.22% from the prior year.
• Net Income towards Common Stockholders climbed to $178.0 million in Q2 2023 per RDY's latest filing, from $169.0 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for RDY reached as high as $178.0 million in Q2 2023 and fell as low as -$108.0 million in Q3 2020.
• A 5-year average of $80.2 million and a median of $105.5 million in 2019 frame the typical range for Net Income towards Common Stockholders.
• The largest YoY upside for Net Income towards Common Stockholders was 121.74% in 2019 against a maximum downside of 214.29% in 2019.
• Year by year, Net Income towards Common Stockholders stood at -$80.0 million in 2019, then sank by 35.0% to -$108.0 million in 2020, then surged by 224.07% to $134.0 million in 2021, then fell by 12.69% to $117.0 million in 2022, then soared by 52.14% to $178.0 million in 2023.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered $178.0 million, $169.0 million, and $117.0 million for Q2 2023, Q1 2023, and Q4 2022 respectively.